The group of inventions relates to the field of medicine and can be used as a medicinal agent in patients suffering from gastritis and gastric and duodenal ulcer disease caused by Helicobacter pylori (H. pylori). The technical result of the group of inventions is eliminating a toxic effect on the body from the therapeutic agents used in achieving high anti-helicobacter activity. This technical result as pertains to the agent is achieved in that the anti-helicobacter agent is a composition consisting of a prebiotic component in the form of oligofructose and inulin, and a metabolic component in the form of calcium lactate, in an effective therapeutic dose that ensures colonization resistance of the gastric mucosa and eradication of Helicobacter pylori. This technical result as pertains to the method is achieved in that the method for using the anti-helicobacter agent comprises orally administering the anti-helicobacter agent according to claims 1-5 in an effective therapeutic dose.

The group of inventions relates to the field of medicine and can be used as a medicinal agent in patients suffering from gastritis and gastric and duodenal ulcer disease caused by Helicobacter pylori (H. pylori). The technical result of the group of inventions is eliminating a toxic effect on the body from the therapeutic agents used in achieving high anti-helicobacter activity. This technical result as pertains to the agent is achieved in that the anti-helicobacter agent is a composition consisting of a prebiotic component in the form of oligofructose and inulin, and a metabolic component in the form of calcium lactate, in an effective therapeutic dose that ensures colonization resistance of the gastric mucosa and eradication of Helicobacter pylori. This technical result as pertains to the method is achieved in that the method for using the anti-helicobacter agent comprises orally administering the anti-helicobacter agent according to claims 1-5 in an effective therapeutic dose.

A problem is to provide a prebiotic which promotes the growth of a butyrate-producing bacterium. A prebiotic composition is described that promotes the growth of a butyrate-producing bacterium which contains alginic acid and/or a salt thereof.

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

Compounds are provided according to Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5a, R.sup.5b, R.sup.6a, and R.sup.6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.

The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

##STR00001##

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

The invention relates to a nutritional composition comprising dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behavior. The invention further relates to a combination of dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behavior.